The role of cytochrome bc₁ inhibitors in future tuberculosis treatment regimens

Area of Science:

• Microbiology
• Drug Discovery
• Infectious Diseases

Background:

• Tuberculosis (TB) is a leading global infectious disease, necessitating improved treatment strategies.
• Developing novel compounds and optimizing regimens are key to shortening TB treatment.
• Targeting essential enzymes like cytochrome bc1 oxidase in Mycobacterium tuberculosis offers a promising avenue.

Purpose of the Study:

• To evaluate cytochrome bc1 inhibitors as adjuncts in TB combination therapy.
• To assess their potential in shortening treatment duration and enhancing sterilisation.
• To explore novel combination strategies for drug-sensitive and drug-resistant TB.

Main Methods:

• Utilized a relapsing mouse model of tuberculosis.
• Tested cytochrome bc1 inhibitors in combination regimens.
• Compared susceptibility of clinical isolates versus laboratory strains to inhibitors.

Main Results:

• Cytochrome bc1 inhibitors significantly enhanced regimen sterilisation in a mouse model.
• These inhibitors substantially reduced the time needed for effective TB treatment.
• Clinical isolates of M. tuberculosis showed greater susceptibility to inhibitors than lab strains.

Conclusions:

• Cytochrome bc1 inhibitors hold potential for developing shorter and more effective TB treatments.
• Novel combination strategies incorporating these inhibitors could improve outcomes for diverse TB forms.
• Further clinical investigation is warranted to validate these findings for TB therapy.